Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TEDC2 is a nuclear protein containing a domain of unknown function (DUF4693), localizing mainly in centrioles and cilia. It forms a structural complex with TEDC1, delta-tubulin (TUBD1), and epsilon-tubulin (TUBE1), all of which are necessary for centriole integrity and assembly; loss of TEDC2 disables triplet microtubule formation and undermines mitotic progression. TEDC2 is widely expressed in normal and cancerous tissues, with upregulation correlated to poor prognosis and reduced immune cell infiltration in lung adenocarcinoma and other cancers. Knockdown of TEDC2 impedes tumor cell proliferation and migration, suggesting its regulatory role in the cell cycle, and highlighting it as a potential biomarker, though not a curated drug target as of now. TEDC2 interacts with proteins involved in DNA replication and centriole function (e.g., CDC45, TUBE1, FEZ1), and may be transcriptionally regulated by tumor suppressor elements (WT1, MZF1, P53).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin epsilon and delta complex protein 2 (TEDC2).